세계의 면역단백질 진단검사 시장 - 규모, 점유율, 동향 분석 보고서 : 검사별, 기술별, 최종 용도별, 유통 채널별, 지역별, 부문별 예측(2025-2030년)

Immunoprotein Diagnostic Testing Market Growth & Trends:

The global Immunoprotein Diagnostic testing market size is expected to reach USD 14.86 billion by 2030, registering a CAGR of 7.7% from 2025 to 2030, according to a new report by Grand View Research, Inc. This growth can be attributed to the rising incidence of chronic diseases.

According to American Heart Association's 2017 statistics, nearly 790,000 people experience heart attack every year in the U.S. In addition, stroke is responsible for 1 in every 20 deaths in the U.S. Hence, WHO is also taking initiatives to reduce the risk of cardiovascular diseases. As a result of the aforementioned factors, the demand for Immunoprotein Diagnostic is expected to rise in order to facilitate rapid diagnosis.

According to WHO, nearly 1.69 million deaths due to lung cancer were registered in 2015 throughout the world. Hence, fast and accurate diagnosis of such chronic diseases has become important to reduce the high mortality rate. Immunoprotein diagnostic devices and reagents have proved to be highly effective in rapidly detecting chronic diseases.

Technological advancements in the field of Immunoprotein Diagnostic have led to introduction of novel products. For instance, LIAISON XL, manufactured by DiaSorin, is a fully automated chemiluminescence analyzer that facilitates complete sample processing. It also measures and evaluates testing samples, thereby, enhancing the efficiency and throughput of the system.

Immunoprotein Diagnostic Testing Market Report Highlights:

• The immunoglobulin diagnostic tests segment accounted for the largest revenue share of the market of 27.1% in 2024. These tests dominate the immunoprotein diagnostic testing market due to their critical role in diagnosing a wide range of conditions, including immune deficiencies, autoimmune disorders, and infectious diseases.
• The infectious disease testing segment accounted for the largest revenue share of the market of 24.2% in 2024. Infectious disease testing is in high demand due to the increasing prevalence of infectious diseases, the need for early and accurate diagnosis, and the critical role these tests play in managing public health.
• The enzyme-based immunoassay segment accounted for the largest revenue share of the market of 25.0% in 2024.
• The retail sales segment accounted for the largest share of the market of 54.1% in 2024. This growth can be attributed to the increased accessibility and convenience for patients.
• The hospitals and clinics segment accounted for the largest revenue share of the market of 44.7% in 2024. Hospitals and clinics serve a large number of patients daily, driving a high demand for diagnostic testing services.
• North America immunoprotein diagnostic testing industry dominated and accounted for a 45.32% share in 2024. The market dominance can be attributed to technological advancements, the high prevalence of chronic diseases, and growing investments in research and development.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Test
  • 1.2.2. Application
  • 1.2.3. Technology
  • 1.2.4. End Use
  • 1.2.5. Distribution Channel
  • 1.2.6. Regional scope
  • 1.2.7. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Test outlook
  • 2.2.2. Application outlook
  • 2.2.3. Technology outlook
  • 2.2.4. End Use outlook
  • 2.2.5. Distribution channel outlook
  • 2.2.6. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Immunoprotein Diagnostic Testing Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising Prevalence of Chronic Diseases
    • 3.2.1.2. Technological Advancements
    • 3.2.1.3. Growing Focus on Personalized Medicine
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High Cost of Diagnostic Tests
    • 3.2.2.2. Regulatory Challenges
• 3.3. Immunoprotein Diagnostic Testing Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Immunoprotein Diagnostic Testing Market: Test Estimates & Trend Analysis

• 4.1. Test Market Share, 2024 & 2030
• 4.2. Segment Dashboard
• 4.3. Global Immunoprotein Diagnostic Testing Market by Test Outlook
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.4.1. Complement System Proteins Diagnostic Tests
    • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.2. Free Light Chain Diagnostic Tests
    • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.3. Haptoglobin Diagnostic Tests
    • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.4. Immunoglobulin Diagnostic Tests
    • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.5. Prealbumin Diagnostic Tests
    • 4.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.6. C-Reactive Protein (CRP) Diagnostic Tests
    • 4.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Immunoprotein Diagnostic Testing Market: Application Estimates & Trend Analysis

• 5.1. Application Market Share, 2024 & 2030
• 5.2. Segment Dashboard
• 5.3. Global Immunoprotein Diagnostic Testing Market by Application Outlook
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.4.1. Infectious Disease Testing
    • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.2. Oncology Testing
    • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.3. Endocrine Testing
    • 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.4. Toxicology Testing
    • 5.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.5. Allergy Testing
    • 5.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.6. Autoimmune Disease Testing
    • 5.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Immunoprotein Diagnostic Testing Market: Technology Estimates & Trend Analysis

• 6.1. Technology Market Share, 2024 & 2030
• 6.2. Segment Dashboard
• 6.3. Global Immunoprotein Diagnostic Testing Market by Technology Outlook
• 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 6.4.1. Radioimmunoassay
    • 6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.2. Enzyme Based Immunoassay
    • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.3. Chemiluminescence Assay
    • 6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.4. Immunofluorescence Assay
    • 6.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.5. Immunoturbidity Assay
    • 6.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.6. Immunoprotein Electrophoresis
    • 6.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Immunoprotein Diagnostic Testing Market: End Use Estimates & Trend Analysis

• 7.1. End Use Market Share, 2024 & 2030
• 7.2. Segment Dashboard
• 7.3. Global Immunoprotein Diagnostic Testing Market by End Use Outlook
• 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 7.4.1. Hospitals and Clinics
    • 7.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.2. Diagnostic Laboratories
    • 7.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.3. Others
    • 7.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Immunoprotein Diagnostic Testing Market: Distribution Channel Estimates & Trend Analysis

• 8.1. Distribution Channel Market Share, 2024 & 2030
• 8.2. Segment Dashboard
• 8.3. Global Immunoprotein Diagnostic Testing Market by Distribution Channel Outlook
• 8.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 8.4.1. Direct Tender
    • 8.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.2. Retail Sales
    • 8.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Immunoprotein Diagnostic Testing Market: Regional Estimates & Trend Analysis

• 9.1. Regional Market Share Analysis, 2024 & 2030
• 9.2. Regional Market Dashboard
• 9.3. Global Regional Market Snapshot
• 9.4. Market Size & Forecasts Trend Analysis, 2018 to 2030:
• 9.5. North America
  • 9.5.1. U.S.
    • 9.5.1.1. Key country dynamics
    • 9.5.1.2. Regulatory framework/ reimbursement structure
    • 9.5.1.3. Competitive scenario
    • 9.5.1.4. Target disease prevalence
    • 9.5.1.5. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.5.2. Canada
    • 9.5.2.1. Key country dynamics
    • 9.5.2.2. Regulatory framework/ reimbursement structure
    • 9.5.2.3. Competitive scenario
    • 9.5.2.4. Target disease prevalence
    • 9.5.2.5. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.5.3. Mexico
    • 9.5.3.1. Key country dynamics
    • 9.5.3.2. Regulatory framework/ reimbursement structure
    • 9.5.3.3. Competitive scenario
    • 9.5.3.4. Target disease prevalence
    • 9.5.3.5. Mexico market estimates and forecasts 2018 to 2030, (USD Million
• 9.6. Europe
  • 9.6.1. UK
    • 9.6.1.1. Key country dynamics
    • 9.6.1.2. Regulatory framework/ reimbursement structure
    • 9.6.1.3. Competitive scenario
    • 9.6.1.4. Target disease prevalence
    • 9.6.1.5. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.2. Germany
    • 9.6.2.1. Key country dynamics
    • 9.6.2.2. Regulatory framework/ reimbursement structure
    • 9.6.2.3. Competitive scenario
    • 9.6.2.4. Target disease prevalence
    • 9.6.2.5. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.3. France
    • 9.6.3.1. Key country dynamics
    • 9.6.3.2. Regulatory framework/ reimbursement structure
    • 9.6.3.3. Competitive scenario
    • 9.6.3.4. Target disease prevalence
    • 9.6.3.5. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.4. Italy
    • 9.6.4.1. Key country dynamics
    • 9.6.4.2. Regulatory framework/ reimbursement structure
    • 9.6.4.3. Competitive scenario
    • 9.6.4.4. Target disease prevalence
    • 9.6.4.5. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.5. Spain
    • 9.6.5.1. Key country dynamics
    • 9.6.5.2. Regulatory framework/ reimbursement structure
    • 9.6.5.3. Competitive scenario
    • 9.6.5.4. Target disease prevalence
    • 9.6.5.5. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.6. Norway
    • 9.6.6.1. Key country dynamics
    • 9.6.6.2. Regulatory framework/ reimbursement structure
    • 9.6.6.3. Competitive scenario
    • 9.6.6.4. Target disease prevalence
    • 9.6.6.5. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.7. Sweden
    • 9.6.7.1. Key country dynamics
    • 9.6.7.2. Regulatory framework/ reimbursement structure
    • 9.6.7.3. Competitive scenario
    • 9.6.7.4. Target disease prevalence
    • 9.6.7.5. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.8. Denmark
    • 9.6.8.1. Key country dynamics
    • 9.6.8.2. Regulatory framework/ reimbursement structure
    • 9.6.8.3. Competitive scenario
    • 9.6.8.4. Target disease prevalence
    • 9.6.8.5. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 9.7. Asia Pacific
  • 9.7.1. Japan
    • 9.7.1.1. Key country dynamics
    • 9.7.1.2. Regulatory framework/ reimbursement structure
    • 9.7.1.3. Competitive scenario
    • 9.7.1.4. Target disease prevalence
    • 9.7.1.5. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.7.2. China
    • 9.7.2.1. Key country dynamics
    • 9.7.2.2. Regulatory framework/ reimbursement structure
    • 9.7.2.3. Competitive scenario
    • 9.7.2.4. Target disease prevalence
    • 9.7.2.5. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.7.3. India
    • 9.7.3.1. Key country dynamics
    • 9.7.3.2. Regulatory framework/ reimbursement structure
    • 9.7.3.3. Competitive scenario
    • 9.7.3.4. Target disease prevalence
    • 9.7.3.5. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.7.4. Australia
    • 9.7.4.1. Key country dynamics
    • 9.7.4.2. Regulatory framework/ reimbursement structure
    • 9.7.4.3. Competitive scenario
    • 9.7.4.4. Target disease prevalence
    • 9.7.4.5. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.7.5. South Korea
    • 9.7.5.1. Key country dynamics
    • 9.7.5.2. Regulatory framework/ reimbursement structure
    • 9.7.5.3. Competitive scenario
    • 9.7.5.4. Target disease prevalence
    • 9.7.5.5. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.7.6. Thailand
    • 9.7.6.1. Key country dynamics
    • 9.7.6.2. Regulatory framework/ reimbursement structure
    • 9.7.6.3. Competitive scenario
    • 9.7.6.4. Target disease prevalence
    • 9.7.6.5. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 9.8. Latin America
  • 9.8.1. Brazil
    • 9.8.1.1. Key country dynamics
    • 9.8.1.2. Regulatory framework/ reimbursement structure
    • 9.8.1.3. Competitive scenario
    • 9.8.1.4. Target disease prevalence
    • 9.8.1.5. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.8.2. Argentina
    • 9.8.2.1. Key country dynamics
    • 9.8.2.2. Regulatory framework/ reimbursement structure
    • 9.8.2.3. Competitive scenario
    • 9.8.2.4. Target disease prevalence
    • 9.8.2.5. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 9.9. MEA
  • 9.9.1. South Africa
    • 9.9.1.1. Key country dynamics
    • 9.9.1.2. Regulatory framework/ reimbursement structure
    • 9.9.1.3. Competitive scenario
    • 9.9.1.4. Target disease prevalence
    • 9.9.1.5. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.9.2. Saudi Arabia
    • 9.9.2.1. Key country dynamics
    • 9.9.2.2. Regulatory framework/ reimbursement structure
    • 9.9.2.3. Competitive scenario
    • 9.9.2.4. Target disease prevalence
    • 9.9.2.5. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.9.3. UAE
    • 9.9.3.1. Key country dynamics
    • 9.9.3.2. Regulatory framework/ reimbursement structure
    • 9.9.3.3. Competitive scenario
    • 9.9.3.4. Target disease prevalence
    • 9.9.3.5. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.9.4. Kuwait
    • 9.9.4.1. Key country dynamics
    • 9.9.4.2. Regulatory framework/ reimbursement structure
    • 9.9.4.3. Competitive scenario
    • 9.9.4.4. Target disease prevalence
    • 9.9.4.5. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 10. Competitive Landscape

• 10.1. Recent Developments & Impact Analysis, By Key Market Participants
• 10.2. Company/Competition Categorization
• 10.3. Vendor Landscape
  • 10.3.1. Key company market share analysis, 2024
  • 10.3.2. Agilent Technologies, Inc.
    • 10.3.2.1. Company overview
    • 10.3.2.2. Financial performance
    • 10.3.2.3. Product benchmarking
    • 10.3.2.4. Strategic initiatives
  • 10.3.3. Danaher Corporation
    • 10.3.3.1. Company overview
    • 10.3.3.2. Financial performance
    • 10.3.3.3. Product benchmarking
    • 10.3.3.4. Strategic initiatives
  • 10.3.4. Thermo Fisher Scientific Inc
    • 10.3.4.1. Company overview
    • 10.3.4.2. Financial performance
    • 10.3.4.3. Product benchmarking
    • 10.3.4.4. Strategic initiatives
  • 10.3.5. PerkinElmer Inc
    • 10.3.5.1. Company overview
    • 10.3.5.2. Financial performance
    • 10.3.5.3. Product benchmarking
    • 10.3.5.4. Strategic initiatives
  • 10.3.6. Bio-Rad Laboratories, Inc
    • 10.3.6.1. Company overview
    • 10.3.6.2. Financial performance
    • 10.3.6.3. Product benchmarking
    • 10.3.6.4. Strategic initiatives
  • 10.3.7. Aurora Biomed Inc.
    • 10.3.7.1. Company overview
    • 10.3.7.2. Financial performance
    • 10.3.7.3. Product benchmarking
    • 10.3.7.4. Strategic initiatives
  • 10.3.8. Tecan Trading AG
    • 10.3.8.1. Company overview
    • 10.3.8.2. Financial performance
    • 10.3.8.3. Product benchmarking
    • 10.3.8.4. Strategic initiatives
  • 10.3.9. Promega Corporation
    • 10.3.9.1. Company overview
    • 10.3.9.2. Financial performance
    • 10.3.9.3. Product benchmarking
    • 10.3.9.4. Strategic initiatives
  • 10.3.10. Charles River Laboratories
    • 10.3.10.1. Company overview
    • 10.3.10.2. Financial performance
    • 10.3.10.3. Product benchmarking
    • 10.3.10.4. Strategic initiatives
  • 10.3.11. Creative Biolabs
    • 10.3.11.1. Company overview
    • 10.3.11.2. Financial performance
    • 10.3.11.3. Product benchmarking
    • 10.3.11.4. Strategic initiatives